Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Thymic Carcinoma Clinical Trial

Official title: Clinical Study of Envolizumab Combined With Radiotherapy for Neoadjuvant Treatment of Locally Advanced Thymic Cancer

Status Recruiting

Clinical Trial Summary

The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.

Clinical Trial Description

For patients with locally advanced thymic carcinoma, it is often difficult to perform radical resection. Numerous studies have reported that neoadjuvant therapy can improve the surgical resection rate of thymic tumors by reducing the extent of tumor invasion and eliminating small metastatic lesions, thereby improving patient survival. However, the efficacy of neoadjuvant immunotherapy combined with chemotherapy is limited. This study intends to conduct a single-arm, phase II clinical trial of neoadjuvant immunotherapy combined with radiotherapy for locally advanced thymic carcinoma to verify the feasibility and safety of neoadjuvant immunotherapy combined with radiotherapy. Meanwhile, the investigators evaluate the pathological remission of postoperative specimens to provide recommendations for establishing pathological evaluation criteria for neoadjuvant therapy for thymic carcinoma. ;

Related Conditions & MeSH terms

• Thymic Carcinoma
• Thymoma
• Thymus Neoplasms

• NCT number: NCT06019468
• Study type: Interventional
• Source: Shanghai Pulmonary Hospital, Shanghai, China
• Contact: Juemin Yu
• Phone: +8615927548511
• Email: yujm96@163.com
• Status: Recruiting
• Phase: Phase 2
• Start date: September 4, 2023
• Completion date: December 30, 2025